OneCellDx, Genetics Institute of America Partner to Launch OncoPredikt HRD Assay

scroll for the Story

~ MORE ~

We mourn for our Evergreen Sweet Smiling Her Excellency !
Robots that reproduce themselves 'aren't giant monsters — yet' Natasha Sweatte reports on an astonishing new “living programmable organism” scientists
Something fresh is surfacing! On Aug. 26, a special edition Splatoon 3 themed Nintendo Switch – OLED Model system will
How to Eat Your Favorite Food || Smart Food Hacks For Every Occasion TIMESTAMPS: 00:19 How to eat spaghetti 01:56
Pandesal Let's bake pandesal, a Filipino breakfast roll with @gidsgids Shout out to @FoxyFolksy for the recipe! Watch More Recipe
The Unlikely Good Samaritan | Full Drama Movie | Eric Roberts The Unlikely Good Samaritan - A modern retelling of
Garlic green beans I'm sharing my delicious and healthy garlic green bean recipe today! You can serve it as a
Finance Minister: 40% Of Millennials Spend Beyond Their Means (Image: The Sun Daily)Finance Minister Tengku Datuk Seri Zafrul Abdul Aziz
Hundreds of thousands of Indian pilgrims begin packing an island in the Ganges for a vast religious festival as Covid-19
The NHS’s booking website allowing people aged 45 and over to schedule their coronavirus vaccination initially crashed, moments after it
DO NOT USE THEIR HOSTING List 1. WebsitePlex very rude in behavioral pattern – the poor resourced American hosting company

Explore S.

→ Story You’re Creating or Missing . . .

Your Story here :

87 people 👁️ing this randomly

OneCellDx, Genetics Institute of America Partner to Launch OncoPredikt HRD Assay

NEW YORK – OneCellDx and the Genetics Institute of America said on Tuesday that they have signed a diagnostics commercialization agreement for OneCellDx’s OncoPredikt HRD Assay.

Under the deal, GIA will create a laboratory-developed test based on OneCellDx’s proprietary, artificial intelligence-enabled algorithm and assay, which is designed to identify genomic signatures associated with homologous recombination deficiency in cancer patients.

The Cupertino, California-based company claims the OncoPredikt test offers improved efficiency and cost savings compared to currently marketed HRD tests. The firm intends to present data on the assay at the upcoming American Society of Clinical Oncology annual meeting.

“Bringing the OncoPredikt HRD test to market will help in accelerating the development of novel pharmaceuticals, improving the care of thousands of patients,” GIA CEO Holly Magliochetti said in a statement.

To validate the test for commercial launch, the Delray Beach, Florida-based lab also plans to run its own study in its CAP-accredited, CLIA-certified facility.

Financial terms of the deal were not disclosed.



Publication author

offline 3 months

SFH Admin

SFH Admin
Comments: 0Publics: 11580Registration: 28-10-2019

Leave a Comment

Password generation